Bristol-Myers Squibb

22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.

iVexSol Inc. specializes in developing lentiviral vector manufacturing technology aimed at addressing the shortage of lentiviral vectors (LVVs), which are essential for gene therapy programs. Established in 2018 and based in Worcester, Massachusetts, the company offers a platform that produces a consistent supply of LVVs, critical for the manufacture of cell and gene therapies (CGTs). By utilizing banks of vector-producing cells, iVexSol's technology significantly increases production capacity while minimizing complexity and development time. This innovative approach not only reduces costs but also accelerates the clinical development timelines, ultimately enhancing patient access to life-saving treatments. The company’s solutions are designed to support researchers and manufacturers in the CGT field, facilitating the treatment of serious conditions such as late-stage cancers and genetic disorders.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Clade Therapeutics is a biopharmaceutical company established in 2020 and based in Cambridge, Massachusetts. The company specializes in the discovery and development of scalable, off-the-shelf stem cell-based medicines aimed at treating a variety of diseases, including cancer and autoimmune disorders. Clade Therapeutics integrates advancements in stem cell biology, immunology, regenerative medicine, and gene editing to create next-generation cell therapies. Its initial focus centers on developing therapies utilizing T cells and other immune cells, thereby enhancing the accessibility and effectiveness of stem cell-derived treatments for patients.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Orna Therapeutics is a biotechnology company focused on developing a new class of fully engineered circular RNA (oRNA) therapeutics aimed at transforming disease treatment. Founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, the company utilizes a proprietary platform that integrates innovative technology for creating circular RNAs designed to enhance protein expression. This platform also incorporates unique delivery solutions to facilitate simplified production, improved formula stability, and superior protein expression, ultimately contributing to advancements in healthcare and therapeutic applications.

Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.

PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines. Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients. Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community to help meet unmet needs for improved safety, and efficacy. We believe the study of Adnectins can help to address these demands. Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion™. Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables discovery productivity by minimizing the timeframe for identifying high-quality candidates. In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company. This acquisition has further accelerated our growth as an industry leader in the discovery and early development of proprietary targeted biologics. Together with Bristol-Myers Squibb, we are developing multiple Adnectin programs for use in the study of potential treatments in a broad range of disease types, including oncology, immunology, and cardiovascular disease.